Cancer mortality data consistently favor people in the US versus their UK counterparts for a variety of reasons.

Quality of Life as an outcome in cancer clinical trials is an often overlooked but key aspect of the outcome of new cancer treatments.

Germline testing for inherited genetic variants is recommended to many people with cancer, yet such useful testing is notably underutilized.